Introduction
Heparin has been reported to inhibit the growth of cells in vitro.
1-s However, due to its anticoagulant properties its value as a therapeutic agent in preventing the aberrant cell proliferation, which is the hallmark of a variety of diseases such as atherosclerosis and pulmonary fibrosis, is severely glycosaminoglycans limited. This limitation would not apply for (GAGs) such as heparan sulphate (HS) which are not very strong anticoagulants. 6 Glycosaminoglycans are linear anionic polyelectrolytes composed of alternating glucosamine and uronic acid sugars. 7 HS, for example, contains uronic acids that are mostly glucuronic with small amounts of iduronic present, the glucosamine units are largely N-acetylated with a small number being N-sulphated. In heparin, the uronic acids differ from those found in HS, as there is more iduronic acid than glucuronic, also the glucosamine pattern is reversed such that the extent of N-sulphation is largely increased over the N-acetylation. 6 To determine whether GAGs other than heparin can prevent cell proliferation, a series of GAGs including HS, dermatan sulphate, and chondroitin sulphate, were examined and tested for their ability to inhibit the replication of mesenchymal cells triggered by growth factors. Heparin was used for comparative purposes. The (Table 3) ). 
